Physician profile
Morvarid Rezaie
NPI 1164692026
$3,512.96
in general payments reported to CMS, 2019-2025
48 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 95% of Hospice and Palliative Medicine (Internal Medicine) providers received nationally (typical 2025 total: $77.77).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $478 · 2021: $556 · 2022: $401 · 2023: $368 · 2024: $424 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,845.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.79 | 2021-2025 | |
| Daiichi Sankyo INC. | $364.38 | 2021-2025 | Enhertu |
| Novo Nordisk INC | $279.11 | 2019-2022 | |
| Allergan, INC. | $175.64 | 2020 | |
| Sirtex Medical INC | $146.41 | 2023 | Sir-Spheres Microspheres |
| Amgen INC. | $145.16 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $134.99 | 2025 | Reblozyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.47 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $124.50 | 2024-2025 | Calquence, Imfinzi, Lynparza |
| Merck Sharp & Dohme LLC | $115.78 | 2019-2025 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $106.41 | 2021-2025 | |
| Janssen Biotech, INC. | $79.63 | 2024-2025 | Erleada, Akeega, Tecvayli |
| Adaptive Biotechnologies Corporation | $59.11 | 2025 | Clonoseq |
| Janssen Pharmaceuticals, INC | $58.41 | 2019-2020 | |
| Forte Bio-Pharma LLC | $56.04 | 2023-2024 | Prolate, Nalocet |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morvarid Rezaie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.